Jose Rubio

Jose M. Rubio, MD, PhD, is Assistant Professor of Psychiatry at the Feinstein Institutes for Medical Research and the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. He is a board-certified psychiatrist and physician-investigator. Dr. Rubio obtained his MD and PhD from the Universitat de Valencia and Universidad Complutense de Madrid (Spain) respectively, and psychiatry residency at the Zucker Hillside Hospital – Hofstra University (New York). His work focuses on relapse prevention, treatment resistance, and antipsychotic effects in schizophrenia. He has received funding from industry and the National Institutes of Health (NIH) to lead multiple research projects, and has received recognition by multiple organizations including the Alpha Omega Alpha Honor Society, the American Society of Clinical Psychopharmacology (ASCP) or the Schizophrenia International Research Society (SIRS). He is an associate member of the American College of Neuropsychopharmacology (ACNP).

After completing residency in 2017, he obtained a Career Development Award by the National Institutes of Health to study biomarker development and relapse in schizophrenia.

As an early career investigator, Dr Rubio has published over 50 articles, focusing on the application of evidence-based interventions in the real world, neuroimaging biomarkers, and prevention of relapse in schizophrenia. Some of the phenomena that he studies is the underutilization of long acting injectable antipsychotics and clozapine, and the neurobiological mechanisms leading to relapse or decrement in antipsychotic efficacy over time.

Dr Rubio regularly lectures on the treatment of schizophrenia in a variety of academic and industry settings. In addition, he supervises residents in a specialized psychosis clinic and co-leads the research track at the Zucker Hillside Hospital psychiatry residency program. Dr. Rubio has received various awards, including the early career investigator travel award for the Schizophrenia International Research Society (SIRS) and the American College of Neuropsychopharmacology (ACNP) and the Alkermes Pathways Award for Junior Investigators.